Pharmaco-Multiomics: A New Frontier in Precision Psychiatry
International Journal of Molecular Sciences · 26.01.2025 · 26 (3) · 1082
DOI: 10.3390/ijms26031082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.01.2025. Verfasst von Dhoha Dhieb und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar. Hauptthemen laut MEDLINE: Precision Medicine, Mental Disorders, Pharmacogenetics, Psychiatry. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by the Qatar National Research Fund (QNRF)/ QRDI, under grant number PPM 06-0530-230047., Qatar National Research Fund (QNRF)/QRDI.
Abstract (Originalsprache)
The landscape of psychiatric care is poised for transformation through the integration of pharmaco-multiomics, encompassing genomics, proteomics, metabolomics, transcriptomics, epigenomics, and microbiomics. This review discusses how these approaches can revolutionize personalized treatment strategies in psychiatry by providing a nuanced understanding of the molecular bases of psychiatric disorders and individual pharmacotherapy responses. With nearly one billion affected individuals globally, the shortcomings of traditional treatments, characterized by inconsistent efficacy and frequent adverse effects, are increasingly evident. Advanced computational technologies such as artificial intelligence (AI) and machine learning (ML) play crucial roles in processing and integrating complex omics data, enhancing predictive accuracy, and creating tailored therapeutic strategies. To effectively harness the potential of pharmaco-multiomics approaches in psychiatry, it is crucial to address challenges such as high costs, technological demands, and disparate healthcare systems. Additionally, navigating stringent ethical considerations, including data security, potential discrimination, and ensuring equitable access, is essential for the full realization of this approach. This process requires ongoing validation and comprehensive integration efforts. By analyzing recent advances and elucidating how different omic dimensions contribute to therapeutic customization, this review aims to highlight the promising role of pharmaco-multiomics in enhancing patient outcomes and shifting psychiatric treatments from a one-size-fits-all approach towards a more precise and patient-centered model of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
ORCID-Profile: Kholoud Bastaki
Förderung
- This study was funded by the Qatar National Research Fund (QNRF)/ QRDI, under grant number PPM 06-0530-230047.
- Qatar National Research Fund (QNRF)/QRDI
Zitieren
APA
Dhieb, D., & Bastaki, K. (2025). Pharmaco-Multiomics: A New Frontier in Precision Psychiatry. International Journal of Molecular Sciences, 26(3), 1082. https://doi.org/10.3390/ijms26031082
Vancouver
Dhieb D, Bastaki K. Pharmaco-Multiomics: A New Frontier in Precision Psychiatry. International Journal of Molecular Sciences. 2025;26(3):1082. doi:10.3390/ijms26031082
BibTeX
@article{Dhieb2025,
author = {Dhieb, Dhoha and Bastaki, Kholoud},
title = {Pharmaco-Multiomics: A New Frontier in Precision Psychiatry},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {3},
pages = {1082},
doi = {10.3390/ijms26031082}
}
EUVIMED